Companies

GSK to buy food allergy drug maker RAPT in $2.2bn deal

January 20, 2026

GSK has announced a $2.2 billion acquisition of RAPT Therapeutics, a California-based biotech firm known for developing treatments for severe food allergies. This marks the first major move by GSK's new CEO, Luke Miels, as the company aims to enhance its portfolio in the biopharmaceutical sector.

GSK to buy food allergy drug maker RAPT in $2.2bn deal

Credit: Theguardian

Key Highlights

GSK's acquisition deal is valued at $2.2 billion.
RAPT Therapeutics specializes in treatments for food allergies and immunologic diseases.
The deal includes an upfront payment of $1.9 billion.
RAPT's stock surged 63% in pre-market trading following the announcement.
This is the first major acquisition under GSK's new CEO, Luke Miels.

Business US news Pharmaceuticals industry UK news Society GSK Allergies

Sources

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.

GSK to buy food allergy drug maker RAPT in $2.2bn deal

Key Highlights

Sources

Related Stories

Microsoft CEO Satya Nadella sends rare warning on AI at Davos, says there will be a ‘tell-tale’ sign of a bubble if…

Kraft Heinz stock falls as Berkshire Hathaway may sell off nearly its entire stake

J&K Bank net profit jumps over 10 pc to Rs 586.73 cr in Q3